From the Journals

Two-dose HPV vaccine trials in teens show effective immunological responses


 

FROM VACCINE

Two-dose human papillomavirus (HPV) vaccine trials appear to show effective immunological responses in teen girls, said Maddalena D’Addario of the University of Bern, Switzerland, and her associates.

In seven controlled trials in 11 countries that directly compared two-dose and three-dose HPV vaccine schedules, teen girls receiving two doses of HPV vaccine with a 6-month interval between them had noninferior antibody responses to HPV16 and HPV18 for at least 2 years, compared with girls receiving three doses.

BVDC/Fotolia.com
In one study in India, teen girls who received two or three doses of HPV vaccines developed no persistent new HPV infections. When comparing different two-dose schedules, those with longer intervals between doses had higher geometric mean concentrations of antibodies.

National Cancer Institute
A limitation to this study is that there is no established immune correlate of protection, so the clinical significance of HPV antibody concentrations is uncertain, the researchers cautioned.

Read more in the journal Vaccine (2017 May 19;35[22]:2892-901).

Recommended Reading

Infliximab safe for recently vaccinated Kawasaki patients
MDedge Pediatrics
Revaccinate HIV-infected teens with hepatitis B vaccine
MDedge Pediatrics
Preterm infants face increased pertussis risk
MDedge Pediatrics
WHO’s malaria pilot vaccine: No silver bullet, but a potential strike at malaria’s heart
MDedge Pediatrics
International travel vaccination updates
MDedge Pediatrics
Rotavirus vaccination in last decade cuts AGE hospitalization
MDedge Pediatrics
Two doses HPV vaccine are as good as three against genital warts
MDedge Pediatrics
Lower-dose aluminum hydroxide–adjuvanted polio vaccine noninferior to standard IPV
MDedge Pediatrics
Safe, effective backup for U.S. MMR vaccine exists
MDedge Pediatrics
Meningococcal B, C vaccines together lead to adequate immune response
MDedge Pediatrics